{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:48:19Z","timestamp":1787500099846,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,30]]},"DOI":"10.1093\/cid\/ciy633","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T15:13:49Z","timestamp":1533136429000},"page":"S35-S41","source":"Crossref","is-referenced-by-count":26,"title":["Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review"],"prefix":"10.1093","volume":"67","author":[{"given":"Ananda S","family":"Bandyopadhyay","sequence":"first","affiliation":[{"name":"Bill & Melinda Gates Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F","family":"Modlin","sequence":"additional","affiliation":[{"name":"Bill & Melinda Gates Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wenger","sequence":"additional","affiliation":[{"name":"Bill & Melinda Gates Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Gast","sequence":"additional","affiliation":[{"name":"Biostatistics Consultant, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"key":"key\n\t\t\t\t2018103001011811400_CIT0001","author":"Global Polio Eradication Initiative"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0002","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0003","volume-title":"Polio Eradication & Endgame Strategic Plan 2013-2018","author":"Global Polio Eradication Initiative","year":"2013"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0004","author":"SAGE"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0005","doi-asserted-by":"crossref","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine\u2014worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0006","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1016\/j.vaccine.2015.09.039","article-title":"Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial","volume":"33","author":"Anand","year":"2015","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0007","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1473-3099(15)00219-4","article-title":"Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study","volume":"15","author":"O\u2019Ryan","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0008","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/S0140-6736(15)00237-8","article-title":"Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial","volume":"386","author":"Sutter","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0009","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1473-3099(15)00488-0","article-title":"Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial","volume":"16","author":"S\u00e1ez-Llorens","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","article-title":"Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial","volume":"388","author":"Asturias","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0011","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1016\/j.vaccine.2017.04.041","article-title":"Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: results from a randomized controlled trial in Latin America","volume":"35","author":"Lopez-Medina","year":"2017","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0012","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1080\/21645515.2017.1288769","article-title":"Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non-inferiority clinical trial","volume":"13","author":"Qiu","year":"2017","journal-title":"Hum Vacc Immunother"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0013","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S1473-3099(17)30358-4","article-title":"Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study","volume":"17","author":"Taniuchi","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0014","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/infdis\/jix577","article-title":"Immunogenicity of different routine poliovirus vaccination schedules: a randomized, controlled trial in Karachi, Pakistan","volume":"217","author":"Saleem","year":"2018","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0015","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1016\/j.vaccine.2017.11.006","article-title":"Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules","volume":"35","author":"Bandyopadhyay","year":"2017","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0016","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1093\/infdis\/jit601","article-title":"Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis","volume":"210","author":"Grassly","year":"2014","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0017","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1473-3099(16)30371-1","article-title":"Unravelling mucosal immunity to poliovirus","volume":"16","author":"Parker","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0018","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/infdis\/162.6.1291","article-title":"Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses","volume":"162","author":"Faden","year":"1990","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0019","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1093\/infdis\/175.Supplement_1.S228","article-title":"Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group","volume":"175","author":"Modlin","year":"1997","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0020","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1056\/NEJMoa054960","article-title":"Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba","volume":"356","author":"Cuba IPV Study Collaborative Group","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0021","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S1473-3099(16)30169-4","article-title":"Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants","volume":"16","author":"Wright","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0022","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/infdis\/jix556","article-title":"Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine","volume":"217","author":"Brickley","year":"2018","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0023","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(14)60934-X","article-title":"Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial","volume":"384","author":"John","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0024","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1126\/science.1255006","article-title":"Polio eradication. Efficacy of inactivated poliovirus vaccine in India","volume":"345","author":"Jafari","year":"2014","journal-title":"Science"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0025","first-page":"529","article-title":"The duration of intestinal immunity after an inactivated poliovirus vaccine booster dose in children immunized with oral vaccine: a randomized controlled trial","volume":"215","author":"John","year":"2017","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2018103001011811400_CIT0026","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2017.03.008","article-title":"Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule","volume":"35","author":"Anand","year":"2017","journal-title":"Vaccine"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/67\/suppl_1\/S35\/26189887\/ciy633.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T14:12:51Z","timestamp":1571667171000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/67\/suppl_1\/S35\/5146678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":26,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2018,10,30]]},"published-print":{"date-parts":[[2018,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy633","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11,15]]},"published":{"date-parts":[[2018,10,30]]}}}